Cargando…
Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716354/ https://www.ncbi.nlm.nih.gov/pubmed/33256390 http://dx.doi.org/10.3324/haematol.2019.230805 |
| _version_ | 1783619142107004928 |
|---|---|
| author | Pettitt, Andrew R. Jackson, Richard Cicconi, Silvia Polydoros, Fotis Yap, Christina Dodd, James Bickerstaff, Matthew Stackpoole, Michael Khan, Umair T. Carruthers, Stacey Oates, Melanie Lin, Ke Coupland, Sarah E. Menon, Geetha Kalakonda, Nagesh McCarthy, Helen Bloor, Adrian Schuh, Anna Duncombe, Andrew Dearden, Claire Fegan, Christopher Kennedy, Ben Walewska, Renata Marshall, Scott Fox, Christopher P. Hillmen, Peter |
| author_facet | Pettitt, Andrew R. Jackson, Richard Cicconi, Silvia Polydoros, Fotis Yap, Christina Dodd, James Bickerstaff, Matthew Stackpoole, Michael Khan, Umair T. Carruthers, Stacey Oates, Melanie Lin, Ke Coupland, Sarah E. Menon, Geetha Kalakonda, Nagesh McCarthy, Helen Bloor, Adrian Schuh, Anna Duncombe, Andrew Dearden, Claire Fegan, Christopher Kennedy, Ben Walewska, Renata Marshall, Scott Fox, Christopher P. Hillmen, Peter |
| author_sort | Pettitt, Andrew R. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7716354 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Fondazione Ferrata Storti |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-77163542020-12-10 Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial Pettitt, Andrew R. Jackson, Richard Cicconi, Silvia Polydoros, Fotis Yap, Christina Dodd, James Bickerstaff, Matthew Stackpoole, Michael Khan, Umair T. Carruthers, Stacey Oates, Melanie Lin, Ke Coupland, Sarah E. Menon, Geetha Kalakonda, Nagesh McCarthy, Helen Bloor, Adrian Schuh, Anna Duncombe, Andrew Dearden, Claire Fegan, Christopher Kennedy, Ben Walewska, Renata Marshall, Scott Fox, Christopher P. Hillmen, Peter Haematologica Letters to the Editor Fondazione Ferrata Storti 2020-02-13 /pmc/articles/PMC7716354/ /pubmed/33256390 http://dx.doi.org/10.3324/haematol.2019.230805 Text en Copyright© 2020 Ferrata Storti Foundation http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
| spellingShingle | Letters to the Editor Pettitt, Andrew R. Jackson, Richard Cicconi, Silvia Polydoros, Fotis Yap, Christina Dodd, James Bickerstaff, Matthew Stackpoole, Michael Khan, Umair T. Carruthers, Stacey Oates, Melanie Lin, Ke Coupland, Sarah E. Menon, Geetha Kalakonda, Nagesh McCarthy, Helen Bloor, Adrian Schuh, Anna Duncombe, Andrew Dearden, Claire Fegan, Christopher Kennedy, Ben Walewska, Renata Marshall, Scott Fox, Christopher P. Hillmen, Peter Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial |
| title | Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial |
| title_full | Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial |
| title_fullStr | Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial |
| title_full_unstemmed | Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial |
| title_short | Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the NCRI CLL210 trial |
| title_sort | lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukemia: final results of the ncri cll210 trial |
| topic | Letters to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716354/ https://www.ncbi.nlm.nih.gov/pubmed/33256390 http://dx.doi.org/10.3324/haematol.2019.230805 |
| work_keys_str_mv | AT pettittandrewr lenalidomidedexamethasoneandalemtuzumaborofatumumabinhighriskchroniclymphocyticleukemiafinalresultsofthencricll210trial AT jacksonrichard lenalidomidedexamethasoneandalemtuzumaborofatumumabinhighriskchroniclymphocyticleukemiafinalresultsofthencricll210trial AT cicconisilvia lenalidomidedexamethasoneandalemtuzumaborofatumumabinhighriskchroniclymphocyticleukemiafinalresultsofthencricll210trial AT polydorosfotis lenalidomidedexamethasoneandalemtuzumaborofatumumabinhighriskchroniclymphocyticleukemiafinalresultsofthencricll210trial AT yapchristina lenalidomidedexamethasoneandalemtuzumaborofatumumabinhighriskchroniclymphocyticleukemiafinalresultsofthencricll210trial AT doddjames lenalidomidedexamethasoneandalemtuzumaborofatumumabinhighriskchroniclymphocyticleukemiafinalresultsofthencricll210trial AT bickerstaffmatthew lenalidomidedexamethasoneandalemtuzumaborofatumumabinhighriskchroniclymphocyticleukemiafinalresultsofthencricll210trial AT stackpoolemichael lenalidomidedexamethasoneandalemtuzumaborofatumumabinhighriskchroniclymphocyticleukemiafinalresultsofthencricll210trial AT khanumairt lenalidomidedexamethasoneandalemtuzumaborofatumumabinhighriskchroniclymphocyticleukemiafinalresultsofthencricll210trial AT carruthersstacey lenalidomidedexamethasoneandalemtuzumaborofatumumabinhighriskchroniclymphocyticleukemiafinalresultsofthencricll210trial AT oatesmelanie lenalidomidedexamethasoneandalemtuzumaborofatumumabinhighriskchroniclymphocyticleukemiafinalresultsofthencricll210trial AT linke lenalidomidedexamethasoneandalemtuzumaborofatumumabinhighriskchroniclymphocyticleukemiafinalresultsofthencricll210trial AT couplandsarahe lenalidomidedexamethasoneandalemtuzumaborofatumumabinhighriskchroniclymphocyticleukemiafinalresultsofthencricll210trial AT menongeetha lenalidomidedexamethasoneandalemtuzumaborofatumumabinhighriskchroniclymphocyticleukemiafinalresultsofthencricll210trial AT kalakondanagesh lenalidomidedexamethasoneandalemtuzumaborofatumumabinhighriskchroniclymphocyticleukemiafinalresultsofthencricll210trial AT mccarthyhelen lenalidomidedexamethasoneandalemtuzumaborofatumumabinhighriskchroniclymphocyticleukemiafinalresultsofthencricll210trial AT blooradrian lenalidomidedexamethasoneandalemtuzumaborofatumumabinhighriskchroniclymphocyticleukemiafinalresultsofthencricll210trial AT schuhanna lenalidomidedexamethasoneandalemtuzumaborofatumumabinhighriskchroniclymphocyticleukemiafinalresultsofthencricll210trial AT duncombeandrew lenalidomidedexamethasoneandalemtuzumaborofatumumabinhighriskchroniclymphocyticleukemiafinalresultsofthencricll210trial AT deardenclaire lenalidomidedexamethasoneandalemtuzumaborofatumumabinhighriskchroniclymphocyticleukemiafinalresultsofthencricll210trial AT feganchristopher lenalidomidedexamethasoneandalemtuzumaborofatumumabinhighriskchroniclymphocyticleukemiafinalresultsofthencricll210trial AT kennedyben lenalidomidedexamethasoneandalemtuzumaborofatumumabinhighriskchroniclymphocyticleukemiafinalresultsofthencricll210trial AT walewskarenata lenalidomidedexamethasoneandalemtuzumaborofatumumabinhighriskchroniclymphocyticleukemiafinalresultsofthencricll210trial AT marshallscott lenalidomidedexamethasoneandalemtuzumaborofatumumabinhighriskchroniclymphocyticleukemiafinalresultsofthencricll210trial AT foxchristopherp lenalidomidedexamethasoneandalemtuzumaborofatumumabinhighriskchroniclymphocyticleukemiafinalresultsofthencricll210trial AT hillmenpeter lenalidomidedexamethasoneandalemtuzumaborofatumumabinhighriskchroniclymphocyticleukemiafinalresultsofthencricll210trial |